View More Recent Stories
-
Altimmune (ALT) Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
-
Altimmune, Inc. (ALT) Reports In-Line Q2 EPS
-
Altimmune (ALT) Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease
-
Altimmune (ALT) Climbs Following Mention in NY Post Article on Weight Loss
-
Altimmune (ALT) Announces Passing of CFO Richard Eisenstadt
-
Altimmune (ALT) Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at ADA
